Oculis Holding AG Warrants (OCSAW)

• Market cap: $270M
• 1 day: -11.15%
• 5 days: -25.79%
• 1 month: -32.99%
• 3 months: -35.57%
• 6 months: -22.11%
• Year to date: 0.97%
• 1 year: 152.68%
• 5 years: 1,002.13%
• 10 years: 1,002.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 49

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

9% more capital invested

Capital invested by funds: $2.14M [Q1] → $2.33M (+$196K) [Q2]

0.13% less ownership

Funds ownership: 0.65% [Q1] → 0.52% (-0.13%) [Q2]

8% less funds holding

Funds holding: 12 [Q1] → 11 (-1) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2